Dupilumab efficacy in patients with type 2 asthma and early F level reductions

The QUEST ( identifier ) and TRAVERSE () studies demonstrated the efficacy of dupilumab, 200 or 300 mg, versus placebo every 2 weeks for 52 weeks (QUEST) and dupilumab, 300 mg, for an additional 96 weeks (TRAVERSE) in patients with uncontrolled, moderate-to-severe asthma. This analysis assessed dupi...

Descripción completa

Detalles Bibliográficos
Autores: Pavord, Ian|||0000-0002-4288-5973, Wechsler, Michael E., Busse, William|||0000-0003-2591-4696, Domingo, Christian|||0000-0001-8358-773X, Xia, Changming, Gall, Rebecca, Pandit-Abid, Nami|||0000-0002-1072-2897, Jacob-Nara, Juby A.|||0000-0002-5372-8762, Radwan, Amr|||0000-0003-1658-5229, Rowe, Paul Jonathan, Deniz, Yamo
Tipo de recurso: artículo
Fecha de publicación:2025
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:319416
Acceso en línea:https://ddd.uab.cat/record/319416
https://dx.doi.org/urn:doi:10.1016/j.jacig.2025.100474
Access Level:acceso abierto
Palabra clave:Dupilumab
Asthma
Feno
Asthma exacerbation
Lung function
Asthma control
Asthma-related quality of life
Early response
Descripción
Sumario:The QUEST ( identifier ) and TRAVERSE () studies demonstrated the efficacy of dupilumab, 200 or 300 mg, versus placebo every 2 weeks for 52 weeks (QUEST) and dupilumab, 300 mg, for an additional 96 weeks (TRAVERSE) in patients with uncontrolled, moderate-to-severe asthma. This analysis assessed dupilumab efficacy in patients from QUEST who enrolled in TRAVERSE and were stratified by a reduction in fractional exhaled nitric oxide (F) level by week 2 of QUEST. Patients with an F level of at least 25 ppb at parent study baseline (PSBL) were defined as those with or without a minimally important F level reduction/response (a ≥20% reduction in patients with an F level of ≥50 ppb and a reduction of.

Similares en LA Referencia